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Appropriate parameters for predicting the aggressiveness of
tumours and their sensitivity to treatment are crucial in cancer
therapy: reliable prognostic factors are needed to select the
optimum treatment and the follow-up strategies. In breast cancer,
the lymph node status is currently one of the best prognostic
factors but alone it is not sufficiently accurate to predict the clin-
ical course of the disease (Mink et al, 1994; Hawkins et al, 1996).
In addition to this classical morphological prognosis factor of
breast carcinoma, many other immunohistochemical markers of
different value exist. They are used to predict the clinical course of
breast cancer at the time of primary treatment, their evaluation
made it possible to offer adjuvant therapy (cytotoxic or endocrine)
for patients with a poor prognosis. In that case, oestrogen and
progesterone status of primary breast tumours have been shown
closely correlated with the therapeutic response to endocrine
therapy (Hawkins et al, 1996; Pichon et al, 1996; Robertson et al,
1996). Although the repertoire of the predictive factors contains
many different markers characterized so far, their optimal combi-
nation remain elusive.
Recently we have characterized two new markers related to cell
proliferation, i.e. SR31747 binding protein (SR-BP-1) and the
human sterol isomerase (hSI) (Silve et al, 1996; Jbilo et al, 1997).
SR-BP-1 was found to be identical to the sigma-1 receptor, and
hSI identical to emopamil binding protein (EBP). These two
proteins show interesting properties: (1) both proteins are co-local-
ized and their expression was observed to be associated with the
endoplasmic reticulum and with the nuclear envelope; (2) these
two proteins bind SR31747 with very similar high affinities high-
lighting the remarkable functional homology between these two
SR31747 receptors (Dussossoy et al, 1999).
The SR31747 molecule is a novel agent that elicits immunosup-
pressive and anti-inflammatory effects. SR31747 has also been
shown to block the proliferation of lymphocytes (Casellas et al,
1994) as well as tumour cells (Labit-Le Bouteiller et al, 1998).
Recently we reported that the binding of SR31747 on hSI was effi-
ciently inhibited by the tamoxifen molecule with an IC50 value in
the nanomolar range (Paul et al, 1998). Tamoxifen is a tryphenyl
ethylene type of non-steroidal anti-oestrogen. It is being widely
used as a therapeutic agent in oestrogen-dependent tumour
therapy, specially in breast cancer. In addition to bind to the
oestrogen receptor (ER) with high affinity, tamoxifen also binds to
sites localized in the AEBS cell microsomal fraction (anti-
oestrogen binding site). We have shown that the AEBS is the EBP
(hSI) (Paul et al, 1998).
Altogether these data made it interesting to test whether the
sigma-1 receptor and hSI would be significant markers for prog-
nostic purposes in breast cancers. To assess their prognostic signif-
icance, we studied their immunohistochemical expression in
primary invasive breast cancers of pre- and post-menauposal
patients. In addition, we investigated their relationship with well
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doi: 10.1054/ bjoc.2000.1162, available online at http://www.idealibrary.com on established prognostic factors, including standard histological
criteria (tumour grading, size, nodal status, etc.), immunohisto-
chemical markers of cell proliferation (Ki-67, MIB-1), and cell
death using the Bcl2 proto-oncogene whose over-expression has
been shown generally associated with ER-positive status and often
with a favourable prognosis (Gee et al, 1994; Johnston et al, 1994;
Hellemans et al, 1995; Buckholm et al, 1997; Slooten et al, 1998).
MATERIALS AND METHODS
Patients
From January 1992 to February 1993, 850 new breast cancers were
diagnosed at the CRLC Department of Pathology (Montpellier,
France). Selection criteria included presentation with primary
invasive breast carcinoma, no preoperative chemotherapy,
endocrine therapy or radiation therapy, sufficient tumour tissue
remaining after diagnosis to allow biochemical quantification of
receptors status and additional immunohistochemical assays (prac-
tically tumour size more than 1-cm diameter), and long-term
follow-up for disease recurrence and death. A total of 95 patients
who satisfied these criteria were chosen.
Surgical treatment included radical mastectomy with axillary
dissection in 58% of the patients and breast conservative sector
resection with axillary dissection in 42% of the patients. After
surgery, all the patients with conservative treatment and 60% with
radical mastectomy underwent combined post-operative radio-
therapy, to eradicate local remainders of the disease. Eighty per
cent received systemic adjuvant therapy, according to the CRLC
routinely assessed clinical management of the disease, and
depending on their age, menopausal status, steroid receptor status
and nodal status: chemotherapy alone for 16 patients, endocrine
therapy alone (tamoxifen) for 58 patients, combined chemotherapy
and endocrine therapy for two patients. Patients were observed for
disease recurrence and death, with a mean follow-up of 64 months.
Tumour samples
At surgery, all patients had a small portion of the tumour removed
which was snap-frozen in liquid nitrogen and stored at –80°C for
ER and progesterone receptor (PR) analysis. The remaining part
of the tumour was fixed in formalin-alcohol for 24 h, parrafin
embedded and subsequently processes with routine techniques
followed by immunohistochemical analysis.
Histopathological study
Five-micron-thick tumour slides were stained with haematoxylin
and eosin for the histopathological study. Tumour grading was
performed according to the methodology of Scarff et al (1957),
modified by Elston et al (1987, 1991). Mitosis counts were
performed in ten high-power fields (HPF = 400 ´) using a Leica
microscope (Leitz DMRB). The tumour size was recorded as the
maximum diameter of the surgically-removed tumour mass.
Axillary lymph node status was assessed for each case by
histopathological examination for a minimum of seven lymph
nodes.
Immunohistochemical analysis
The expressions of the sigma-1 receptor, hSI, Bcl2 and the prolif-
erative marker Ki-67 were analysed using an immunohistochem-
ical procedure. The antibodies used were: a mouse monoclonal
anti-sigma-1 receptor (Jbilo et al, 1997), a rabbit polyclonal anti-
hSI raised against the N-terminal (2–25) peptide of the hSI (its
specificity was assessed using the competitive immunogene
peptide as a reference) (Dussossoy et al, 1999), a mouse mono-
clonal anti-Bcl2 antibody (Dako, clone 124) and the anti-Ki-67
MIB-1 antibody (Immunotech). Their respective dilution used
were 1:400, 1:100, 1:50 and 1:100. These four antibody character-
istics (sources, dilutions) are summarized in Table 1. Two-
micrometre-thick paraffin-embedded sections of tumour samples
were analysed, mounted on Dako silanized slides. All procedures
were carried out at room temperature. Immunohistochemical
detection of the different markers was done using the strepta-
vidin–biotin (LSAB) method (Dako LSAB kit). The sections,
which had been preincubated with 3% hydrogen peroxide (H2O2)
solution for 10 min to block endogenous peroxidase, were incu-
bated for 20 min with blocking agent, for 2 h with the different
primary antibodies, they were then rinsed and incubated with the
secondary antibody for 10 min. They were then incubated with
streptavidin conjugated to horseradish peroxidase: a positive
reaction was visualized with 3-amino-9-ethylcarbazol. Before
mounting, the sections were counterstained with Mayer’s haema-
toxylin. For the negative control, the primary antibody was
omitted and replaced by an irrelevant antibody (monoclonal mouse
anti-human IgG (Dako)). For the positive control, sections from
normal breast tissue were used.
The different marker’s immunoreactivity was then evaluated by
two observers using a high-power lense (400 ´). Cytoplasmic
(sigma-1 receptor, hSI, Bcl2) and nuclear (MIB-1) labelling were
evaluated using a semiquantitative method taking into account the
staining intensity and the number of stained cells in different
random fields: 0 means no staining or less than 10% tumour cells
labelled, 1 means a weak staining from 10 to 30% tumour cells, 2
means a moderate staining in more than 30% tumour cells, and 3
means an intense and diffuse staining.
Quantification of steroid hormone receptors
Breast tumour specimens were frozen in liquid nitrogen immedi-
ately after surgical removal and send to the Steroid Receptor
Laboratory, then they were pulverized in liquid nitrogen, cytosols
were prepared and the dextran-coated charcoal assay was used to
determine the receptor status with 3H oestradiol and 3H
progesterone as labelled ligands. The results were expressed as
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Table 1 Antibodies used in this study
Antigen Source Pretreatment
antibody dilution
SR-BP-1 Mouse monoclonal antibody, NT
Sigma-1 receptor Sanofi-Synthelabo 1/400
hSI Rabbit polyclonal antibody, MW
Human sterol isomerase Sanofi-Synthelabo 1/100
Bcl2 Mouse monoclonal antibody, MW
Clone 124 1/50
Dako A/S, Denmark
Ki-67 MIB-1, MW
Immunotech, France 1/100
MW: microwave epitope retrieval; NT: no pretreatmentfentomols per milligram of tissue (fmol mg–1). Values greater than
10 fmol mg–1 were considered as positive.
Statistical analysis
Correlations between the clinico-pathological data and the expres-
sion of the four immunohistochemical markers analysed were
assessed using standard c2 tests. The median values of different
variables were compared using the Kruskal–Wallis test.
Locoregional disease relapse and/or distant metastasis and death
due to cancer were considered as end points for disease-free
survival (DFS). DFS curves starting from the date of surgery were
plotted using the Kaplan–Meier method. The statistical signifi-
cance of each marker was calculated using the log-rank test. For
all statistical analyses, a P-value < 0.05 was considered statisti-
cally significant. P-values over 0.10 are noted ‘NS’ for non signif-
icant. For further statistical analysis, two groups of patients were
defined: patients who underwent adjuvant endocrine therapy
(tamoxifen) and total population, including patients with or
without adjuvant therapy (endocrine or chemotherapy).
RESULTS
Patient characteristics (Table 2)
The analysis of the four markers under study is performed with 95
patients. Patients were characterized according to their age, their
menopausal status (assessed using serum gonadotrophin, oestra-
diol and progesterone measurements in pre and peri-menopausal
patients), the size of the tumour, the axillary nodal status, the TNM
staging (based on the UICC Atlas criteria, 1992) and the therapy
type. The mean age of the patients was 61 years (range 32–83);
79% of the patients were post-menopausal. Among the pre-
menopausal patients, 60% were younger than 45 years. Within this
population, eight patients had recurrences (locoregional, three;
controlateral, five) after a mean time of 38 months (range 23–64),
18 patients had distant metastasis after a mean time of 44 months
(range 23–73). The number of deaths was four after a mean time of
44 months (range 41–72).
Histopathological findings (Table 2)
Clinical tumour size was less than 20 mm in 57% of cases (T1),
between 20 and 50 mm in 39% (T2), and more than 50 mm in 4%
(T3). Eighty-five per cent of the cancers were of infiltrating ductal
type, 11% were of infiltrating lobular type, 4% were of other types.
According to the Elston and Ellis modification of the Bloom and
Richardson grading system (SBR), 24% of patients were grade I,
41% grade II and 35% grade III. Forty-two per cent of the patients
were axillary lymph node-positive, the other being lymph node-
negative.
Steroid receptor status
ER-positive status was observed in 65% of the tumours with a
median concentration of 59 fmol mg–1 for ER-positive patients
(range 10–441 fmol mg–1). Sixty-nine per cent of the tumours were
PR-positive with a median concentration of 76 fmol mg–1 (range
10–576 fmol mg–1). Positivity for both receptors was observed in
55% of the tumours (52 cases). Only one of the receptors (ER or
PR) was positive in 25% of the tumours (24 cases), and ER and PR
were both negative in 19 cases (20%).
Immunohistochemical findings
Immunohistochemical distribution of the sigma-1 receptor
expression (Figure 1 A, B)
The sigma-1 receptor was present in normal breast sections,
heterogeneously distributed in epithelial ducts and acinar struc-
tures, and the immunostaining was never strong (Figure 1B).
Positive cells showed a cytoplasmic granular staining, very often
with a perinuclear localization. Metaplastic apocrine epithelial
cells of microcyst structures were also stained. In addition to the
epithelial component, several other structures showed weak
immunostaining, particularly the smooth muscle cells of vascular
sections, the myofibroblastic cells of the stromareaction, and a few
histiocytic and mononuclear inflammatory cells. Positive imuno-
staining for sigma-1 receptor was observed in 72 tumours (76%).
Positively stained tumour cells appeared to be homogeneously and
strongly stained. The immunostaining was cytoplasmic but the
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Table 2 Population characteristics
Features Number of patients %
Total population 95
Population characteristics
Age (years)
Median 61
Range (min–max) 32–83
Menopause
Pre- 20 21
Post- 75 79
Therapeutic characteristics
Adjuvant therapy
None 19 18
Endocrine therapy 58 62
Chemotherapy 18 20
Disease status
Tumour grade
I2 2 2 4
II 38 40
III 32 33
No grading 3a 3
Tumour size
T1 54 57
T2 37 39
T3 4 4
Nodal status
N0 55 58
N1 40 42
TNM stage
I3 7 3 8
IIA 34 35
IIB 21 22
IIIA 3 5
Steroid receptor status
ER status
Positive 62 65
Negative 33 35
PR status
Positive 66 69
Negative 29 31
ER median (range) 59 (10–441)
PR median (range) 76 (10–576)
a Breast carcinomas of special types.granular and perinuclear pattern seemed to be less obvious (Figure
1A). The intraductal component of the infiltrating cancers gener-
ally did not show any staining, or only a weak one.
Immunohistochemical distribution of the hSI expression
(Figure 1 C–E)
Normal breast components (ductal and acinar epithelial cells)
more often showed a weak cytoplasmic immunostaining (Figure
1E). Positive immunostaining for hSI was observed in 65 tumours
(68%). The immunostaining of the epithelial tumoural cells was
heterogeneous, with variable intensity within the same tumour and
between patients. Cytoplasmic elements were stained, including
the endoplasmic reticulum and the nuclear envelope, and often
with an increase in the staining along the cytoplasmic envelope
(Figure 1 C, D). The intraductal components of the tumours
showed no or weak staining.
Immunohistochemical expression of Bcl2 and Ki-67
Bcl2 reactivity was observed in 75 patients (79%). The staining
was always cytoplasmic (data not shown). MIB-1 anti-Ki-67 anti-
body nuclear staining was weak for 29 patients (31%), inter-
mediate for 23 patients (24%) and strong for 43 patients (45%).
Associations between sigma-1 receptor and hSI expression
with clinicopathological variables (Tables 3 and 4)
No correlation was shown between the sigma-1 receptor expres-
sion and the age, tumour grade, tumour size, or nodal status of the
patients. However, an absence of detectable sigma-1 receptor
expression was most often observed in premenopausal patients 
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A
B
C
D
E
Figure 1 Immunostaining of (A) infiltrating breast cancer or (B) normal
breast acini with anti-sigma-1 receptor antibody; magnification is ´ 200.
Immunostaining of (C) infiltrating breast cancer or (E) normal breast duct with
anti-hSI antibody; magnification is ´ 200. A zoom (D, magnification is ´ 400)
showed a strong immunostaining of infiltrating breast cancer with anti-hSI
antibody with an increase along the inner border of the cell(P = 0.09). There was a significant relationship between the sigma-
1 receptor expression and the steroid receptor status (P = 0.03). ER
and PR were more often negative in the absence of sigma-1
receptor immunoreactivity (39%) than in its presence (14%) (P =
0.008). There was a significant relationship between the sigma-1
receptor immunoreactivity and PR status. Among PR-negative
patients, sigma-1 receptor immunostaining was positive in 59% of
patients, whereas among PR-positive patients, sigma-1 receptor
immunostaining was positive in 83% of patients (P = 0.01). No
correlation was found between sigma-1 receptor immunoreactivity
and ER status. There was no correlation between positive sigma-1
receptor expression and receptor levels. For hSI immunoreactivity,
there was no relationship with the age, menopausal status, tumour
grade, tumour size or nodal status of the patients (Table 3). There
was a significant correlation between hSI expression and the
steroid receptor status (P = 0.027). An absence of immunoreac-
tivity was essentially associated with a positive receptor status for
ER and/or PR (P = 0.098). There was a non-significant correlation
between hSI expression and ER status (P = 0.11), while the
absence of hSI immunoreactivity tended to be associated with ER
positivity. Nevertheless, among ER-positive patients, the median
ER values were significantly greater with hSI immunoreactivity
(102 fmol mg–1) than with its absence expression (40 fmol mg–1)
(P = 0.004). There was no significant correlation between PR
status and hSI immunoreactivity or between PR values and hSI
expression (Table 4). In the tamoxifen-treated subgroup with posi-
tive PR status, the median PR value was greater in the group with
highly positive hSI immunoreactivity (292 fmol mg–1), than in
the group without or only slightly positive hSI expression
(73 fmol mg–1) (P = 0.056).
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Table 3 Relationship between sigma-1 receptor, hSI expression and clinicopathological parameters in primary operable breast carcinomas
Factors Sigma-1 receptor immunoreactivity (0/1,2,3) hSI immunoreactivity (0/1,2,3)
Negative Positive P-value Negative Positive P-value
n = 23 n = 72 n = 30 n = 65
Age NS NS
<45 years 3 (13%) 10 (14%) 4 (13%) 9 (14%)
45–54 4 (17%) 20 (28%) 7 (23%) 17 (26%)
<54 16 (70%) 42 (58%) 19 (64%) 39 (60%)
Menopausal status 0.09 NS
Non- 2 (9%) 18 (25%) 4 (13%) 16 (24%)
Post- 21 (91%) 54 (75%) 26 (87%) 49 (76%)
Tumour size NS NS
T1 13 (57%) 41 (57%) 19 (64%) 35 (54%)
T2 9 (39%) 28 (39%) 10 (33%) 25 (41%)
T3 1 (4%) 3 (4%) 1 (3%) 3 (5%)
Tumour grade NS NS
1 3 (14%) 19 (27%) 8 (29%) 14 (22%)
2 8 (36%) 30 (43%) 11 (39%) 27 (42%)
3 11 (50%) 21 (30%) 9 (32%) 23 (36%)
Nodal status NS NS
0 11 (48%) 44 (61%) 18 (60%) 33 (54%)
1 12 (52%) 28 (39%) 12 (40%) 28 (46%)
Table 4 Relationship between global expression of sigma-1 receptor and hSI antibodies with receptor status in primary operable breast carcinomas
Receptor status Sigma-1 receptor immunoreactivity (0/1,2,3) hSI immunoreactivity (0/1,2,3)
Negative Positive P-value Negative Positive P-value
Association ER, PR 0.034 0.027
ER–, PR– 9 (39%) 10 (14%) 3 (10%) 16 (36%)
ER–, PR+ 1 (4%) 13 (18%) 4 (13%) 10 (23%)
ER+, PR– 3 (13%) 7 (10%) 5 (17%) 5 (11%)
ER+, PR+ 10 (44%) 42 (58%) 18 (60%) 18 (40%)
Association ER, PR: 0.008 0.098
ER–, PR– 9 (39%) 10 (14%) 3 (10%) 16 (25%)
ER+ or PR+ 14 (61%) 62 (86%) 27 (90%) 49 (75%)
ER:
Status:– 10 (44%) 23 (32%) NS 7 (23%) 26 (40%) 0.11
+ 13 (56%) 49 (68%) 23 (77%) 39 (60%)
*values 119 (13–214) 55 (10–441) NS 40 (10–326) 102 (11–441) 0.004
PR:
Status:– 12 (52%) 17 (24%) 0.01 8 (27%) 21 (32%) NS
+ 11 (48%) 55 (76%) 22 (73%) 44 (68%)
Median (range) 40 (10–346) 82 (10–576) NS 55 (10–576) 82 (10–448) NSAssociations between sigma-1 expression, hSI expression,
Bcl2 and Ki-67 immunostaining (Table 5)
No significant relationship was found between sigma-1 receptor
and hSI expressions. There was no significant relationship
between the sigma-1 receptor expression, hSI expression and Ki-
67 immunostaining. A significant positive relationship was noted
between sigma-1 receptor and Bcl2 positivity (P = 0.017), and an
inverse relationship between hSI and Bcl2 protein expression
(P = 0.035).
Prognostic relevance
Compared to other possible clinico-pathological prognostic factors,
sigma-1 receptor and hSI expression was associated with DFS.
In our study, there was a positive relationship between the posi-
tive sigma-1 immunostaining and DFS (5-year DFS = 81% vs
60%;  P = 0.09). A significant relationship was found between DFS
and the inverse co-expression of sigma-1 and hSI, with more fail-
ures occurring among patients who expressed hSI without sigma-1
expression (5-year DFS = 48%; P = 0.007; Figure 2). Patients with
Bcl2 positivity had a higher DFS rate (81% at 5 years) than
patients who did not express Bcl2 (59% at 5 years, P = 0.004;
Figure 3). Increased DFS was noted when Bcl2 positivity was
associated with sigma-1 positivity (DFS = 85% vs 58%; P =
0.0004; Figure 4), and the absence of hSI (DFS = 90% vs 70%; 
P = 0.061; Figure 5). These results were more significant in the
group of patients who received tamoxifen. There was a close
correlation between sigma-1 positivity and longer DFS (DFS =
84% vs 58%; P = 0.045; Figure 6). Shorter DFS was observed with
a simultaneous absence of sigma-1 receptor expression and posi-
tive hSI antibody immunoreactivity (DFS = 45% vs 85%; P =
0.003; Figure 7). As compared with Bcl2 expression, sigma-1 and
hSI expression suggested that they had a greater effect on DFS. In
the group of patients with a loss of Bcl2 protein, DFS was shorter
for patients with positive hSI immunoreactivity (DFS = 40%) than
for patients with an absence of hSI expression (DFS = 100%), but
due to the small number of patients this result was non-significant
(Figure 8). Moreover, for patients with positive Bcl2 expression,
the positive sigma-1 immunoreactivity improved DFS (5-year
DFS = 90% vs 50% for patients with an absence of sigma-1
expression;  P = 0.001; Figure 9).
DISCUSSION
This report describes the comparison of two new markers, the
sigma-1 receptor and hSI, with other clinico-pathological prog-
nostic factors in a group of 95 patients with operable primary
breast carcinoma. Correlations between the expression of these
new markers with the age, menopausal status, tumour size, its
nodal status and the steroid receptor status were assessed. Their
Sigma-1 receptor and human sterol isomerase in breast cancer 1963
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Figure 3 Disease-free survival: patients were dichotomized as being 
Bcl2-positive or Bcl2-negative
Figure 2 Disease-free survival: sigma-1-negative/hSI-positive patients
versus other all patients
Figure 4 Disease-free survival: Bcl2-positive/sigma-1-negative versus all
other patients
Figure 5 Disease-free survival: Bcl2-positive/hSI-negative versus all
other patientsrelationships with the DFS, the tumour proliferative rate (Ki-67)
and with the expression of the Bcl2 proto-oncogene were also
investigated. We studied the sigma-1 receptor and hSI expression
by immunohistochemical analysis to address their prognostic
value for the patient outcome and their potential modulation in
response to endocrine therapy.
A multivariate statistical analysis was conducted and showed
that among the classical morphological prognosis factors of breast
carcinoma and the other immunohistochemical markers studied,
only the SBR grading was correlated with DFS in the total popula-
tion analysed (n = 95). However, the subgroup of the patients who
received an adjuvant endocrine therapy (n = 58), two other factors:
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Figure 6 Disease-free survival: sigma-1-positive versus sigma-1-negative
in the tamoxifen-treated group
Figure 7 Disease-free survival: sigma-1-negative/hSI-positive versus all
other patients in the tamoxifen-treated group
Figure 8 Disease-free survival: sigma-1-negative/hSI-positive versus all
other patients in the tamoxifen-treated group and Bcl2-negative group
Figure 9 Disease-free survival: sigma-1-negative/hSI-positive versus all
other patients in the tamoxifen-treated group and Bcl2-positive group
Table 5 Overall correlations between the immunohistochemical markers
Sigma1 receptor expression hSI expression
Negative Positive P-value Negative Positive P-value
hSI
Negative 7 (30%) 23 (32%) NS – – –
Positive 16 (70%) 49 (68%) – –
Sigma-1
Negative – – – 7 (23.3%) 16 (24.6%) NS
Positive – – 23 (76.7%) 49 (75.4%)
Bcl2
Negative 9 (39%) 11 (15%) 0.017 5 (17%) 15 (23%) 0.035
+ 5 (22%) 10 (14%) 1 (3%) 14 (22%)
++/+++ 9 (39%) 51 (71%) 24 (80%) 36 (55%)
MIB-1
1 6 (26%) 23 (32%) 9 (30%) 20 (31%)
2 5 (22%) 18 (25%) NS 10 (33%) 13 (15%) NS
3 12 (52%) 31 (43%) 11 (37) 32 (54%)Sigma-1 receptor and human sterol isomerase in breast cancer 1965
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age and menopausal status of the patients were also significantly
correlated with DFS. Histopathological tumour grading in breast
carcinomas, despite its subjectivity, remains an important prog-
nostic factor, as reported in several studies (Hawkins et al, 1996;
Pichon et al, 1996).
Receptor status, along with age and menopausal status, were
decisive factors for an adjuvant endocrine therapy in the present
study. However, this status was not significantly correlated with
DFS. Some authors have reported that the receptor status has a
prognostic effect within the first 5 years after surgery, but is no
longer pertinent after 8 years of follow-up (Colett et al, 1996;
Hawkins et al, 1996; Pichon et al, 1996). In the large series of
patients reported by Pichon et al, ER and PR status, as compared
with established prognostic factors such as TNM and histological
grading, were of relatively limited predictive value. Their major
interest remains in therapeutic guidance for subgroups of breast
cancer patients. These findings are in agreement with our present
data. Steroid receptors represented the only biological parameter
in this decision. A recent study reported that Bcl2 immunostaining
was a more accurate predictor of response than ERs (Gee et al,
1994). The Bcl2 protein in our study group, i.e. in the overall
population and in the subgroup of patients treated by adjuvant
endocrine therapy, was the strongest predictor of outcome and
response to endocrine therapy. It was compared with the two
markers investigated.
Our findings showed a significant correlation between the
sigma-1 receptor expression and PR status. Sigma-1 expression
occurred essentially with PR-positive tumours, whereas hSI
expression had a significant inverse correlation with ER status.
There was also a close correlation between Bcl2 protein expres-
sion with sigma-1 expression and an inverse correlation with hSI
expression. A highly significant relationship was noted between
the presence or not of Bcl2 protein and the receptor status. Bcl2
over-expression occurred when ER and/or PR were positive, as
also previously demonstrated (Gee et al, 1994; Johnston et al,
1994; Hellemans et al, 1995; Bukholm et al, 1997). These inter-
reactions between receptor status, Bcl2 protein and these two
new markers suggest a possible relationship between these
proteins. Although the endogenous ligands of sigma sites have
not yet been clearly identified, Su (1991) suggested that they
belong to the steroid family and possibly include progesterone.
We thus considered that they could have a biochemical relation-
ship through their ligands. Furthermore, it is interesting to note
that the promoter region sequence of sigma-1 receptor contains
binding sites for progesterone, suggesting that sigma-1 receptor
expression is regulated by this steroid (Seth et al, 1997). The
findings of this study are in accordance with this hypothesis.
Altogether these data indicate that sigma-1 receptor expression
may be functionally linked to the PR status and thus could be an
additional parameter in the choice of patients to undergo
endocrine therapy.
The functional activities of sigma-1 and hSI have not yet been
clearly elucidated. Nevertheless, these proteins are likely involved
in the sterol synthesis on the grounds of following data (Silve et al,
1996): (1) the sequence similarity of yeast sterol isomerase and the
sigma receptor binding protein; (2) the mammalian EBP, which is
very structurally different from sigma receptor binding protein and
yeast sterol isomerase, displays sterol isomerase activity when
expressed in yeast; (3) the cellular location of these two proteins in
the nuclear membrane and in the ER, which also includes other
cholesterol synthesis proteins such as HMG-CoA.
The influence of sigma-1 and hSI expression (alone or
combined) was also investigated on DFS. They were found to be
significantly associated with DFS, and even more so in the
subgroup of tamoxifen-treated patients. The loss of hSI expression
and the positive sigma-1 expression was associated with the
highest DFS rate, while the presence of hSI and the absence of
sigma-1 expression was associated with a lower DFS rate.
The combined loss of sigma-1 expression with the presence of
hSI expression was strongly associated with the lowest DFS rate.
They seemed to have more of an influence on the DFS in the group
of tamoxifen-treated patients.
We conclude that sigma-1 and hSI markers in primary breast
carcinomas may have an application in the choice of patients who
may benefit from an adjuvant endocrine therapy, in association
with an evaluation of the steroid receptor status. Adjuvant
endocrine therapy could be recommended for patients with posi-
tive expression of sigma-1 antibody and loss of hSI expression. In
contrast, the group of patients showing a loss of sigma-1 expres-
sion associated with positive hSI expression, despite the positive
receptor status, did not have a significant improvement in DFS
with adjuvant endocrine therapy. This patient group could
probably have benefited from a higher DFS with adjuvant
chemotherapy. A larger study should be undertaken to confirm
these results and test them for the therapeutic management of
patients with primary operable breast carcinomas.
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